Eli Lilly agreed to pay Versanis shareholders in cash, which will consist of an upfront payment and potentially subsequent payments if Versanis achieves certain “development and sales milestones.”
related investing news
The Oakland, California-based Versanis, which was founded in 2021 by biotech investment firm Aditum Bio, has one experimental drug for obesity and potentially other conditions.
An estimated 40% of U.S. adults are obese. Analysts project that the global weight loss drug market could be worth $100 billion by around 2030.
Versanis’s drug, bimagreumab, binds directly to certain cells in the body to reduce fat mass.
The company is studying bimagreumab in a phase two trial in adults who are overweight or obese, and in another trial that compares the treatment with Novo Nordisk’s Wegovy and Ozempic.
Bimagreumab works differently from Novo Nordisk’s drugs and similar treatments from Indianapolis-based Eli Lilly. Those drugs, known as GLP-1 agonists, mimic hormones produced in the gut called incretins to suppress a person’s appetite.
But Versanis said combining bimagreumab with those incretin-based therapies could potentially lead to better outcomes for people living with obesity and cardiometabolic conditions, which includes diabetes, kidney disease and disorders affecting the heart.
Eli Lilly is working on several obesity treatments.
The company’s once-weekly experimental injection, retatrutide, helped overweight or obese patients lose up to 24% of their weight after 48 weeks.
That surpasses the weight reduction caused by other obesity drugs.
Eli Lilly’s experimental obesity pill, orforglipron, also helpd overweight or obese patients lose up to 14.7% of their body weight after 36 weeks.
The company is also pushing to approve its type 2 diabetes treatment, Mounjaro, for obesity.